INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

FDMT4D Molecular Therapeutics, Inc.

CIK 0001650648

EDGAR filingsOpen in network
Disclosed transactions4
Buys / sells0 / 2
Max Insider Score25
Connections3with evidence

FDMT · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
BS
Bizily ScottChief Legal Officer
FDMT4D Molecular Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$41K
9,810 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Bizily ScottChief Legal Officer · Jun 25, 2026
  • ← Insider ofevidence
    Kirn DavidDirector, See Remarks · Jun 23, 2026
25
BS
Bizily ScottChief Legal Officer
FDMT4D Molecular Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$118K
9,810 sh
Jun 23, 2026
Jun 25, 2026
traded Jun 23, 2026
+2d
SEC FORM 4

Evidence

3
BS
Bizily ScottChief Legal Officer
FDMT4D Molecular Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
9,810 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC FORM 4

Evidence

23
KD
Kirn DavidDirector, See Remarks
FDMT4D Molecular Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.20M
114.7K sh
Jun 22, 2026Jun 23, 2026
traded Jun 22, 2026
+1dSEC FORM 4

Evidence